W R Kim

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 4:1798-804. 2004
  2. ncbi request reprint Epidemiology and natural history of primary biliary cirrhosis in a US community
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1631-6. 2000
  3. ncbi request reprint Outcome of liver transplantation for hepatitis B in the United States
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Liver Transpl 10:968-74. 2004
  4. ncbi request reprint The impact of competing risks on the observed rate of chronic hepatitis C progression
    W Ray Kim
    Mayo Clinic and Foundation Ch10, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    Gastroenterology 127:749-55. 2004
  5. ncbi request reprint Deaths on the liver transplant waiting list: an analysis of competing risks
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:345-51. 2006
  6. ncbi request reprint The use of decision analytic models to inform clinical decision making in the management of hepatocellular carcinoma
    W Ray Kim
    Mayo Clinic College of Medicine, Division of Gastroenterology, Rochester, MN 55905, USA
    Clin Liver Dis 9:225-34. 2005
  7. ncbi request reprint Motion - the available treatments for hepatitis C are cost effective: arguments against the motion
    W Ray Kim
    Department of Medicine, Mayo Clinic and Foundation, Rochester 55905, USA
    Can J Gastroenterol 16:710-5. 2002
  8. ncbi request reprint The burden of hepatitis C in the United States
    W Ray Kim
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, USA
    Hepatology 36:S30-4. 2002
  9. ncbi request reprint Burden of liver disease in the United States: summary of a workshop
    W Ray Kim
    Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hepatology 36:227-42. 2002
  10. ncbi request reprint Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Hepatology 32:924-9. 2000

Research Grants

Detail Information

Publications65

  1. ncbi request reprint Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 4:1798-804. 2004
    ..Delta MELD is predictive of death only within 4 d of the event; however, part of this correlates with the dying process itself, thus limiting Delta MELD's utility in survival prediction models...
  2. ncbi request reprint Epidemiology and natural history of primary biliary cirrhosis in a US community
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1631-6. 2000
    ..We report the incidence and prevalence of this condition in the general population. We also examined the validity of the Mayo natural history model for PBC among these unselected patients from the community...
  3. ncbi request reprint Outcome of liver transplantation for hepatitis B in the United States
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Liver Transpl 10:968-74. 2004
    ..In conclusion, these data underscore the effectiveness of therapeutic innovations that have occurred in the past two decades and indicate timely and widespread adoption of these measures by transplant centers nationwide...
  4. ncbi request reprint The impact of competing risks on the observed rate of chronic hepatitis C progression
    W Ray Kim
    Mayo Clinic and Foundation Ch10, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    Gastroenterology 127:749-55. 2004
    ..A simulation experiment was conducted to measure the magnitude of the effect of competing risks on the observed rate of fibrosis progression of CHC...
  5. ncbi request reprint Deaths on the liver transplant waiting list: an analysis of competing risks
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:345-51. 2006
    ..In conclusion, the competing risk analysis method is useful in estimating the risk of death among patients awaiting liver transplantation...
  6. ncbi request reprint The use of decision analytic models to inform clinical decision making in the management of hepatocellular carcinoma
    W Ray Kim
    Mayo Clinic College of Medicine, Division of Gastroenterology, Rochester, MN 55905, USA
    Clin Liver Dis 9:225-34. 2005
    ....
  7. ncbi request reprint Motion - the available treatments for hepatitis C are cost effective: arguments against the motion
    W Ray Kim
    Department of Medicine, Mayo Clinic and Foundation, Rochester 55905, USA
    Can J Gastroenterol 16:710-5. 2002
    ..Given these limitations, vis- -vis the expense, toxicity and yet limited effectiveness of the currently available antiviral agents, one should not blindly accept a conclusion that treatment for hepatitis C is cost effective...
  8. ncbi request reprint The burden of hepatitis C in the United States
    W Ray Kim
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, USA
    Hepatology 36:S30-4. 2002
    ..e., those with infection for 20 years or longer), suggesting a continued rise in the burden of HCV in the United States in the foreseeable future...
  9. ncbi request reprint Burden of liver disease in the United States: summary of a workshop
    W Ray Kim
    Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hepatology 36:227-42. 2002
  10. ncbi request reprint Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Hepatology 32:924-9. 2000
    ..These data, combined with our previous study, demonstrate its applicability in a wide spectrum of disease severity, ranging from early, ambulatory-phase disease to decompensated cirrhosis necessitating liver transplantation...
  11. ncbi request reprint Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates
    W R Kim
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 6:489-94. 2000
    ..The abbreviated risk score is a convenient method to quickly estimate the risk score in patients with PBC. An abbreviated score of 6 may be consistent with the current minimal listing criteria in liver transplant candidates...
  12. ncbi request reprint Outcome of hospital care of liver disease associated with hepatitis C in the United States
    W R Kim
    Outcomes Research Unit Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 33:201-6. 2001
    ..This study provides new estimates regarding the public health impact of HCV, for use in health policy decisions and cost-effectiveness analyses of preventive and therapeutic interventions...
  13. ncbi request reprint Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 6:453-8. 2000
    ..We advise that liver transplant candidates with RVsys >/=50 mm Hg undergo right heart catheterization to fully characterize pulmonary hemodynamics...
  14. ncbi request reprint Quality of life before and after liver transplantation for cholestatic liver disease
    C R Gross
    University of Minnesota, Minneapolis, MN, USA
    Hepatology 29:356-64. 1999
    ..The patients' QOL 1 year after LT could not be predicted by pretransplantation variables used in this study...
  15. pmc Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization
    W R Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Hepatology 30:395-400. 1999
    ..While efforts must be made to improve the outcome following retransplantation, a more critical evaluation may be warranted for late retransplantation candidates...
  16. ncbi request reprint Natural history of hepatitis B virus infection: an update for clinicians
    Surakit Pungpapong
    Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:967-75. 2007
    ....
  17. doi request reprint OPTN/SRTR 2012 Annual Data Report: Liver
    W R Kim
    Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
    Am J Transplant 14:69-96. 2014
    ..Graft survival for deceased donor pediatric transplants was 92.8% at 30 days. Medicare paid for some or all of the care for more than 30% of liver transplants in 2010. ..
  18. pmc Daclizumab induction therapy in liver transplant recipients with renal insufficiency
    S K Asrani
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Aliment Pharmacol Ther 32:776-86. 2010
    ..The role of interleukin 2 (IL-2) receptor antibodies to avoid the nephrotoxic effects of calcineurin inhibitors in the early post-liver transplant (LT) period is not well defined...
  19. doi request reprint Serum sodium, renal function, and survival of patients with end-stage liver disease
    Young Suk Lim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Hepatol 52:523-8. 2010
    ..We investigate the role of serum creatinine and sodium, and glomerular filtration rate (GFR) as determinants of survival in patients with ESLD...
  20. doi request reprint Impact of MELD on waitlist outcome of retransplant candidates
    H J Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Am J Transplant 10:2652-7. 2010
    ..We conclude that by and large, primary and ReTx candidates fare equitably under the current MELD-based allocation system, which has contributed to a significant increase in the probability of LTx...
  21. doi request reprint The global impact of hepatic fibrosis and end-stage liver disease
    Young Suk Lim
    Division of Gastroenterology and Hepatology PL 6, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Liver Dis 12:733-46, vii. 2008
    ..Moreover, the burden of chronic liver disease is projected to increase, due in part to the increasing prevalence of end-stage liver disease and HCC secondary to NAFLD and HCV...
  22. doi request reprint Simultaneous liver-kidney transplantation summit: current state and future directions
    M K Nadim
    Division of Nephrology, Department of Medicine, University of Southern California, Los Angeles, CA, USA
    Am J Transplant 12:2901-8. 2012
    ..Modifications to the current guidelines for SLK and a research agenda were proposed...
  23. ncbi request reprint Mortality and hospital utilization for hepatocellular carcinoma in the United States
    W Ray Kim
    Division of Gastroenterology and Hepatology and Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 129:486-93. 2005
    ..Hospital service utilization was estimated based on length of stay, total hospitalization charges, and principal procedures...
  24. pmc Trends in waiting list registration for liver transplantation for viral hepatitis in the United States
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 137:1680-6. 2009
    ....
  25. ncbi request reprint The model for end-stage liver disease (MELD)
    Patrick S Kamath
    Advanced Liver Disease Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 45:797-805. 2007
    ..It is possible that the addition of variables that are better determinants of liver and renal function may improve the predictive accuracy of the model. Efforts at further refinement and validation of the MELD score will continue...
  26. doi request reprint Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease
    W Ray Kim
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Hepatology 47:1363-70. 2008
  27. ncbi request reprint Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease
    Charmaine A Stewart
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 13:1366-71. 2007
    ..HE may provide additional prognostic information independent of MELD, which warrants prospective validation...
  28. pmc Impact of pretransplant hyponatremia on outcome following liver transplantation
    Byung Cheol Yun
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 49:1610-5. 2009
    ..The incidence of CPM correlates with hyponatremia, although its overall incidence is low. Incorporation of serum sodium in organ allocation may not adversely affect the overall post-OLT outcome...
  29. doi request reprint Hyponatremia and mortality among patients on the liver-transplant waiting list
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    N Engl J Med 359:1018-26. 2008
    ..Under the current liver-transplantation policy, donor organs are offered to patients with the highest risk of death...
  30. pmc Epidemiology of hepatitis B in the United States
    W Ray Kim
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 49:S28-34. 2009
    ....
  31. ncbi request reprint Medical and economic impact of autoimmune hepatitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, S W Rochester, MN 55905, USA
    Clin Liver Dis 6:649-67. 2002
    ..As a result, the ability to plan for disease management strategies in AIH that require the allocation of scarce resources will be feasible...
  32. ncbi request reprint Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation
    David J Vanness
    Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Health Econ 11:551-66. 2002
    ..The approach allows flexibility in assessing treatment in various counterfactual premises and quantifies the global effect of parametric uncertainty on a decision-maker's confidence in adopting one therapy over the other...
  33. ncbi request reprint Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis
    Jayant A Talwalkar
    Transplant Center, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:431-5. 2003
    ..To determine the level of association between minimal listing criteria (MLC) recognition and outcomes associated with waiting list registration for liver transplantation (LT)...
  34. ncbi request reprint MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients
    Walter K Kremers
    The William J von Liebig Transplant Center, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:764-9. 2004
    ..68). In conclusion, liver allocation within the Status 1 designation may need to be further stratified by diagnosis, and MELD score may be useful for prioritizing FHF-NA candidates...
  35. ncbi request reprint Changing epidemiology of hepatitis B in a U.S. community
    W Ray Kim
    Division of Gastroenterology and Hepatology Mayo 16E, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hepatology 39:811-6. 2004
    ..69) and age greater than 40 years (OR = 2.32 per decade). In conclusion, in this Midwestern community, chronic HBV infection was predominantly seen in immigrants from endemic parts of the world...
  36. ncbi request reprint Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 125:1364-9. 2003
    ..The epidemiology of primary sclerosing cholangitis (PSC) in the United States is unknown. We report the incidence, clinical spectrum, and outcomes of PSC in Olmsted County, Minnesota...
  37. pmc The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measure
    Patrick S Kamath
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Liver Dis 13:63-6. 2009
    ..8, indicating excellent discrimination...
  38. ncbi request reprint MELD accurately predicts mortality in patients with alcoholic hepatitis
    Winston Dunn
    Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 41:353-8. 2005
    ..MELD is a useful clinical tool for gauging mortality and guiding treatment decisions in patients with AH, particularly those complicated by ascites and/or encephalopathy...
  39. doi request reprint OPTN/SRTR 2011 Annual Data Report: liver
    W R Kim
    Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN, USA
    Am J Transplant 13:73-102. 2013
    ..Incidence of acute rejections increases with time after transplant. Posttransplant lymphoproliferative disorder remains an important concern in pediatric recipients...
  40. doi request reprint Serum aminotransferase activity and mortality risk in a United States community
    Tae Hoon Lee
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Hepatology 47:880-7. 2008
    ..78 for >2x ULN). SMR was also higher for abnormal ALT (SMR = 1.21 for 1-2x ULN and 1.51 for >2x ULN). In contrast, normal AST or ALT was associated with a risk of death lower than expected (SMR 0.95 for AST, 0.61 for ALT)...
  41. ncbi request reprint Development and maintenance of a community-based hepatitis C registry
    Barbara P Yawn
    Department of Clinical Research, Olmsted Medical Center, Rochester, MN 55904, USA
    Am J Manag Care 8:253-61. 2002
    ..To develop a model for community-population- or health system-based registries of all patients with diagnosed hepatitis C, to facilitate clinical care and epidemiologic studies...
  42. pmc Increased prevalence and mortality in undiagnosed celiac disease
    Alberto Rubio-Tapia
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 137:88-93. 2009
    ..The historical prevalence and long-term outcome of undiagnosed celiac disease (CD) are unknown. We investigated the long-term outcome of undiagnosed CD and whether the prevalence of undiagnosed CD has changed during the past 50 years...
  43. pmc Organ allocation for chronic liver disease: model for end-stage liver disease and beyond
    Sumeet K Asrani
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Curr Opin Gastroenterol 26:209-13. 2010
    ..Prognostic models have been proposed to either refine or improve the current MELD-based liver allocation...
  44. doi request reprint Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis
    K Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Gut 57:814-20. 2008
    ..The aim of this study was to determine risk factors for 6-week mortality, and re-bleeding within 5 days in patients with cirrhosis and AVH...
  45. pmc Donor race does not predict graft failure after liver transplantation
    Sumeet K Asrani
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Gastroenterology 138:2341-7. 2010
    ..We evaluated the extent to which the center where the transplantation surgery was performed and other potential confounding factors might account for the observed association between donor race and graft failure...
  46. pmc Alcoholic liver disease-related mortality in the United States: 1980-2003
    Helga Paula
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 105:1782-7. 2010
    ....
  47. ncbi request reprint Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Eur J Gastroenterol Hepatol 16:519-26. 2004
    ....
  48. ncbi request reprint Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites
    Luke T Evans
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 37:897-901. 2003
    ..In addition, the organisms cultured from ascitic fluid in outpatients are predominantly gram positive. A reassessment of diagnostic criteria for spontaneous bacterial peritonitis in outpatients may be required...
  49. ncbi request reprint Diagnosis and 10-year follow-up of a community-based hepatitis C cohort
    Barbara P Yawn
    Department of Clinical Research, Olmsted Medical Center, 210 Ninth St, SE, Rochester, MN 55904, USA
    J Fam Pract 51:135-40. 2002
    ..To determine the health care follow-up and treatment associated with physician-diagnosed hepatitis C (HCV) in a community-based population...
  50. ncbi request reprint Risk factors for mortality after surgery in patients with cirrhosis
    Swee H Teh
    Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 132:1261-9. 2007
    ..The aim of this study was to determine the risk factors for postoperative mortality in patients with cirrhosis...
  51. pmc Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat
    Liliana Gazzuola Rocca
    Department of Clinical Research, Olmsted Medical Center, Rochester, Minn 55904, USA
    Ann Fam Med 2:116-24. 2004
    ..The rate of hepatitis C treatment is low, however. This study explores the frequency of hepatitis C treatment, documented discussions of treatment consideration, and the reasons treatment may not be offered in a community population...
  52. pmc Endothelial nitric oxide synthase gene variation associated with chronic kidney disease after liver transplant
    Kiran Bambha
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, USA
    Mayo Clin Proc 85:814-20. 2010
    ..To identify single nucleotide polymorphisms (SNPs) associated with risk of developing chronic kidney disease (CKD), a prevalent comorbidity, after liver transplant (LT)...
  53. doi request reprint Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis
    Sumeet K Asrani
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 52:1360-70. 2010
    ..47, 95% CI = 1.14-5.36), rash (RR = 7.57, 95% CI = 1.75-32.70), ulcers (RR = 7.44, 95% CI = 2.03-27.28), and discontinuation of therapy (RR = 3.61, 95% CI = 1.32-9.89)...
  54. ncbi request reprint Survival after liver transplantation: Is racial disparity inevitable?
    Tae Hoon Lee
    William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN, USA
    Hepatology 46:1491-7. 2007
    ..CONCLUSION: These data demonstrate that as a proof of principle, minority OLT recipients should not necessarily expect an OLT outcome inferior to that of Caucasians...
  55. doi request reprint Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C
    Stanley S Liu
    Viral Hepatitis Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Gastroenterol 44:e178-85. 2010
    ..The aim of our study was to examine the influence of antidepressant treatment and whether this improves the likelihood of completing therapy...
  56. ncbi request reprint Employment and health insurance in long-term liver transplant recipients
    Catherine Rongey
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Transplant 5:1901-8. 2005
    ..1), physical function score>52.4 (OR=3.6) and general health score>33.3 (OR=7.6) were significantly associated with employment. These data may help identify high-risk pre-OLT patients for intervention measures such as work rehabilitation...
  57. ncbi request reprint Liver transplantation is effective, but is it cost-effective?
    Kiran Bambha
    Liver Transpl 9:1308-11. 2003
  58. ncbi request reprint Pretransplantation disease severity and posttransplantation outcome
    W Ray Kim
    Liver Transpl 9:124-5. 2003
  59. ncbi request reprint Hepatic vein pressure gradient >10 mm Hg: prognostic or reflective?
    W Ray Kim
    Gastroenterology 134:641; author reply 641-2. 2008
  60. doi request reprint Benefits of "the benefit model" in liver transplantation
    W Ray Kim
    Hepatology 48:697-8. 2008
  61. ncbi request reprint Evidence-based incorporation of serum sodium concentration into MELD
    Scott W Biggins
    University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1652-60. 2006
    ..Serum sodium (Na) concentrations have been suggested as a useful predictor of mortality in patients with end-stage liver disease awaiting liver transplantation...
  62. doi request reprint Mortality attributable to cholestatic liver disease in the United States
    Flavia D Mendes
    Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, USA
    Hepatology 47:1241-7. 2008
    ..These changes may be attributable to liver transplantation or ursodeoxycholic acid. In contrast, mortality from PSC remained largely unchanged, highlighting the need for more effective therapeutic strategies...
  63. ncbi request reprint Is the change in MELD score a better indicator of mortality than baseline MELD score?
    Patrick S Kamath
    Liver Transpl 9:19-21. 2003
  64. ncbi request reprint Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Liver Transpl 13:867-74. 2007
    ..65-0.85). In conclusion, MELD showed a suboptimal discriminative ability to predict survival in BCS. This was explained by the highly variable degree of liver dysfunction and hence clinical outcome in BCS in contrast to ESLD...
  65. ncbi request reprint A glossary of economic terms
    Naoki Chiba
    Eur J Gastroenterol Hepatol 16:563-5. 2004

Research Grants8

  1. Models for Optimal Liver Transplant Outcomes
    W Ray Kim; Fiscal Year: 2006
    ..abstract_text> ..
  2. Epidemiology and Impact of Hepatitis C in the Community
    W Ray Kim; Fiscal Year: 2007
    ..abstract_text> ..
  3. Models for Optimal Liver Transplant Outcomes
    W Ray Kim; Fiscal Year: 2007
    ....
  4. Models for Optimal Liver Transplant Outcomes
    W Ray Kim; Fiscal Year: 2009
    ....
  5. Models for Optimal Liver Transplant Outcomes
    W Ray Kim; Fiscal Year: 2010
    ....